Summary
Global Markets Direct’s, ‘Irritable Bowel Syndrome - Pipeline Review, H1 2016’, provides an overview of the Irritable Bowel Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4D Pharma Plc
A. Menarini Industrie Farmaceutiche Riunite Srl
Alfa Wassermann S.p.A
Allergan Plc
Ardelyx, Inc.
Astellas Pharma Inc.
CJ HealthCare Corp.
Enterome Bioscience SA
Innovate Biopharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Lexicon Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Protagonist Therapeutics Inc.
RaQualia Pharma Inc.
RedHill Biopharma Ltd.
SK Biopharmaceuticals Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Synergy Pharmaceuticals, Inc.
Synthetic Biologics, Inc.
Takeda Pharmaceutical Company Limited
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome - Overview 11
Irritable Bowel Syndrome - Therapeutics under Development by Companies 12
Irritable Bowel Syndrome - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Irritable Bowel Syndrome - Products under Development by Companies 17
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19
4D Pharma Plc 19
A. Menarini Industrie Farmaceutiche Riunite Srl 20
Alfa Wassermann S.p.A 21
Allergan Plc 22
Ardelyx, Inc. 23
Astellas Pharma Inc. 24
CJ HealthCare Corp. 25
Enterome Bioscience SA 26
Innovate Biopharmaceuticals, Inc. 27
Ironwood Pharmaceuticals, Inc. 28
Kissei Pharmaceutical Co., Ltd. 29
Lexicon Pharmaceuticals, Inc. 30
Ono Pharmaceutical Co., Ltd. 31
Pfizer Inc. 32
Protagonist Therapeutics Inc. 33
RaQualia Pharma Inc. 34
RedHill Biopharma Ltd. 35
SK Biopharmaceuticals Co., Ltd. 36
Sumitomo Dainippon Pharma Co., Ltd. 37
Synergy Pharmaceuticals, Inc. 38
Synthetic Biologics, Inc. 39
Takeda Pharmaceutical Company Limited 40
Irritable Bowel Syndrome - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
ASP-1017 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASP-7147 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bedoradrine sulfate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Blautix - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CJ-14199 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
crofelemer DR - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DA-6886 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DSP-6952 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
EB-120 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
eluxadoline - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ibodutant - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
larazotide acetate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
linaclotide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
lovastatin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
LX-1033 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ondansetron hydrochloride CR - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ONO-2952 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PBF-677 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
plecanatide - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
pregabalin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
relenopride hydrochloride - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
rifaximin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RQ-00202730 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RQ-00310941 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
solabegron hydrochloride - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TAK-480 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
tenapanor hydrochloride - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Irritable Bowel Syndrome - Recent Pipeline Updates 94
Irritable Bowel Syndrome - Dormant Projects 130
Irritable Bowel Syndrome - Discontinued Products 135
Irritable Bowel Syndrome - Product Development Milestones 136
Featured News & Press Releases 136
Apr 11, 2016: RedHill Biopharma Initiates Phase II Study of BEKINDA for Irritable Bowel Syndrome 136
Mar 07, 2016: Napo and Salix Settle Litigation 137
Feb 29, 2016: Video Alert: Updated 2016 Direct-to-Consumer Awareness Campaign Available for LINZESS (linaclotide) 137
Feb 26, 2016: Clinical Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma 138
Feb 24, 2016: Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with Linaclotide for the Treatment of Adults with IBS-C 138
Feb 17, 2016: Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation 139
Feb 11, 2016: RedHill Biopharma Announces Successful PK Study with BEKINDA 12 mg and Submission to FDA of IBS-D Phase II Study Protocol 139
Jan 21, 2016: VIBERZI (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine 140
Jan 19, 2016: Clinical Update on Blautix, a novel treatment for Irritable Bowel Syndrome 141
Jan 19, 2016: Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) 142
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 143
Disclaimer 144
List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Development by Companies, H1 2016 (Contd..1) 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 (Contd..1) 18
Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H1 2016 19
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 20
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H1 2016 21
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2016 22
Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H1 2016 23
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H1 2016 24
Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H1 2016 25
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2016 26
Irritable Bowel Syndrome - Pipeline by Innovate Biopharmaceuticals, Inc., H1 2016 27
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 28
Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 29
Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016 30
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 31
Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H1 2016 32
Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H1 2016 33
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H1 2016 34
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H1 2016 35
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 36
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 37
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H1 2016 38
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H1 2016 39
Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 40
Assessment by Monotherapy Products, H1 2016 41
Number of Products by Stage and Target, H1 2016 43
Number of Products by Stage and Mechanism of Action, H1 2016 45
Number of Products by Stage and Route of Administration, H1 2016 47
Number of Products by Stage and Molecule Type, H1 2016 49
Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 94
Irritable Bowel Syndrome - Dormant Projects, H1 2016 130
Irritable Bowel Syndrome - Dormant Projects (Contd..1), H1 2016 131
Irritable Bowel Syndrome - Dormant Projects (Contd..2), H1 2016 132
Irritable Bowel Syndrome - Dormant Projects (Contd..3), H1 2016 133
Irritable Bowel Syndrome - Dormant Projects (Contd..4), H1 2016 134
Irritable Bowel Syndrome - Discontinued Products, H1 2016 135
List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 41
Number of Products by Top 10 Targets, H1 2016 42
Number of Products by Stage and Top 10 Targets, H1 2016 42
Number of Products by Top 10 Mechanism of Actions, H1 2016 44
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 44
Number of Products by Routes of Administration, H1 2016 46
Number of Products by Stage and Routes of Administration, H1 2016 46
Number of Products by Molecule Types, H1 2016 48
Number of Products by Stage and Molecule Types, H1 2016 48
